TW434016B - Pharmaceutical tablet containing famciclovir and a process for its preparation - Google Patents
Pharmaceutical tablet containing famciclovir and a process for its preparation Download PDFInfo
- Publication number
- TW434016B TW434016B TW086100335A TW86100335A TW434016B TW 434016 B TW434016 B TW 434016B TW 086100335 A TW086100335 A TW 086100335A TW 86100335 A TW86100335 A TW 86100335A TW 434016 B TW434016 B TW 434016B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- pharmaceutical
- lactose
- item
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
^34016 - A7 B7_ 五、發明説明(1 ) 本發明係關於一種新穎醫藥產物調配物。 ^---ί--^------ (請先閱讀背面之注^^項再填寫本莧) 欧洲專利182024號(發給Beecham Group p.Lc.的)實例2説 明製備法西克樂維耳的方法,法西克樂維耳爲盤西克樂維 耳(penciclovir)化合物經口使用的化合物,盤西克樂維耳具 抗病毒活性,可用於對抗由疱疹病毒引起的感染,如I型單 純性疮療,II型單純性疱奢,及水痘帶狀疮療病毒,也可 用於對抗B型肝炎病毒。盤西克樂維耳及其抗病毒活性見 "Abstracts of 14th Int. Congress of Microbiology" » Manchester,England 7-13 September 1986之摘要P·VI 1_5, p. 193 (Boyd', etal·〉所揭示。 法西克樂維耳較佳是以含125毫克,250毫克,500毫克 或750毫克活性成分的錠劑給予。如一般習用錠劑一樣, 此錠劑含賦形劑,如乳糖,瀝粉己醉酸鈉及硬脂酸嫫,賦 形劑總量至少爲15 %。一般以無水乳糖爲主要的賦形劑, 以使活性成分的性質在打片過程中不會起改變。 賦形劑的含量越高,任一给予劑量的錠的大小會越大。 特別是含活性劑500毫克及750毫克時的錠劑,在錠劑含約 76%法西克樂維耳時,其卵圓形面積分別爲18毫米χ8.5毫 米及21毫米xlO毫米,這麼大的錠會使病人抱怨。 鯉濟部中央揉率局貝工消费合作社印製 現已發現,可將法西克樂維耳調配成含賦形劑少於15 % 的錠劑,在此範面内不會使法西克樂維耳的打片性質發生 改變。 因之,本發明提供一種醫藥錠劑,其中法西克樂維耳爲 活性成分,且其中法费克樂维耳的重量百分比爲錠的85% -4- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 434016 A7 B7 經濟部中央標率局員工消費合作社印装 五、發明説明(2 或更大。 此處所給予的重量百分比値’除非另有説明,以任何 錠劑核重量爲準,此錠劑核可作塗覆,例如作膜塗覆。 逋宜的錠劑含少於15%,少於10%,少於5〇/〇,較佳是 0%的乳糖或其他類似軾形劑,如微結晶纖維素β 適宜的錠劑所含法西克樂維耳的重量百分比大於85〇/〇, 86%,87°/。,88%,89%,90% 或 91%。較佳是含盡可能 高重量百分比的法西克樂維耳。法西克樂維耳可爲逋宜的 醫藥上可接受的形式,例如鹽的形式,溶劑化物或多晶形 物的形式》 錠劑組合物中所含習用的賦形劑包括羥两基纖維素,達 例如5%或達3 %,爽粉乙醇酸納,達例如15%,10%,7% ,或5%,及硬脂酸鎂達例如2%或1 % » 錠劑可用遑於醫藥錠劑用的塗復做塗後》 此等錠劑可以技藝已知的習用方法·製備。較佳的方法是 ,將法西克樂維耳用賦形剗,例如羥丙基纖維素,製成顆 粒,以使活性成分因物理形狀的任何改變的影響減至最低 。將顆粒縴過,乾燥,然後於另外的賦形劑混合,製成打 片混合物。錠劑係打成遑於所需劑量的大小於重量,然後 視需要做塗覆。 下述實例説明本發明》 實例 括號内之百分比値爲在大不列類聯合王國及北愛爾蘭, 美S及其他世界各國醫藥管理當局登記之法西克樂維耳錠 -5. 本紙張尺度適用中國國家揉率(CNS ) A4規格(210X297公釐) {請先閱讀背面之注項再填寫本頁) ,τ r 4 3 4016、 Α7 Β7 五、發明説明(3 ) 的百分比值。 成分 %重量/重量 β/。重量/1 法西克樂維耳 91.42 (75.66) 羥丙基纖維素 2.83 (2.34) 澱粉G醇酸鈉 5.00 (5.00) 硬脂酸鎂 0.75 (0_75) 無水乳糖 0 (16.25) 500毫克劑量的錠核重爲近5 47毫克,750毫克劑量的錠 核重爲近820毫克》 作成塗覆錠時,塗覆增加錠核重的2.5%,500毫克劑量 的塗覆錠重爲560毫克,750毫克劑量的塗覆錠重爲840毫 克。 此等錠的製铺是,以法西克樂維耳舆羥丙基纖維素作乾 混合,然後於高剪顆粒器内將混合物舆水製成顆粒。將濕 物質歸過,乾燥,研磨。研磨過的顆粒澱粉乙醇酸鈉及硬 脂酸鎂混合,製成打片混合物。以逍於所需錠劑強度打成 大小及重量適宜的錠,然後作水性膜塗覆》 製成的750毫克的錠的_圓面積爲19毫米x9毫米,5〇0 毫克的錠的卵圓面積爲17毫米χ8毫米。 (請先聞讀背面之注項再填寫本頁) -^夺 訂 經濟部中央橾準局貝工消费合作杜印袋 -6- 本紙張尺度適用中國國家揉準(CNS ) A4規格(210 X 297公釐)
Claims (1)
- 434〇 1 6 ^ 86100335號專利申請案 —範圍修正^g88 六、申請專利範圍 A8 B8 HiΜ h 一種醫藥錠#丨,其中活性成分是法西克樂維耳 .(famciclovir),且其中法西克樂維耳的重量百分比是錠劑 的8 5 0/〇或更多。 2. 根據申請專利範圍第1項之蝥藥錠劑,其含少於15%的乳 糖》 3. 根據申請專利範園第1或2項之醫藥鍵劑,其含少於5%的 乳糖。 4. 根據申請專利範園第1或2項之醫藥鍵劑,其含〇 %的乳糖 5. 根據申請專利範圍第1或2項之醫藥錠劑 維耳的重量百分比是鍵劑的90 %或更多。 6, 根據申請專利範圍第!或2項之醫藥錠劑, 其中法西克樂 其成分如下: (請先閲讀背面之注意事項再填寫本頁) 成分 %^量/重量 法西克樂維耳 91.42 羥丙基纖維素 2.83 澱粉乙醇酸鈉 5.00 硬脂酸鎂 0.75 無水乳糖 0 經濟部中央揉率局貝工消费合作社印裝 7. —種製備根據申請專利範圍第1或2項之錠劑之方法,其 中先將法西克樂維耳與賦形劑製成顆粒,然後壓成錠。 本纸張AA制tBB家搞準〖CNS ) A4iUS· ( 21GX297公釐) 修正 ! \/2: 本、 年月叫1么、一 1 補充 89. 7.13 | »—------一 申請曰期 86.01.14. 案 號 一 .〜— 86100335 類 别 (以上各攔由本局填註) A4 C4 434016 (89年7月修正頁) 翁|專利説明書 _、發明 新型 名稱 1、發明 創作 人 中 文 英 文 姓 名 國 籍 住、居所 姓 名 (名稱) 含法西克樂維耳(famcic丨ovir)之醫藥鍵刺及其製法 PHARMACEUTICAL TABLET CONTAINING FAMCICLOVIR AND A PROCESS FOR ITS PREPARATION 1. 麥可強格林威 2. 珍妮佛瑪莉史菝特 1-2英國 1. 英國西蘇塞郡沃辛市克拉倫敦路史密斯克林貝克曼製藥2. 英國西蘇塞郡沃辛市克拉倫敦路史密斯克林貝克曼製藥 英商史密斯克林貝克曼公司 裝 訂 經濟部智",!|4^段工”費合作社印製 國 藉 英國 三、申请人 住、居所 (事務所) 代表人 姓 名 英國米德萊赛省班特福市新界 大衛.羅伯茲 ^紙張尺度適用中國國家標^ ((:1^)八4规格(210乂297公釐) 434〇 1 6 ^ 86100335號專利申請案 —範圍修正^g88 六、申請專利範圍 A8 B8 HiΜ h 一種醫藥錠#丨,其中活性成分是法西克樂維耳 .(famciclovir),且其中法西克樂維耳的重量百分比是錠劑 的8 5 0/〇或更多。 2. 根據申請專利範圍第1項之蝥藥錠劑,其含少於15%的乳 糖》 3. 根據申請專利範園第1或2項之醫藥鍵劑,其含少於5%的 乳糖。 4. 根據申請專利範園第1或2項之醫藥鍵劑,其含〇 %的乳糖 5. 根據申請專利範圍第1或2項之醫藥錠劑 維耳的重量百分比是鍵劑的90 %或更多。 6, 根據申請專利範圍第!或2項之醫藥錠劑, 其中法西克樂 其成分如下: (請先閲讀背面之注意事項再填寫本頁) 成分 %^量/重量 法西克樂維耳 91.42 羥丙基纖維素 2.83 澱粉乙醇酸鈉 5.00 硬脂酸鎂 0.75 無水乳糖 0 經濟部中央揉率局貝工消费合作社印裝 7. —種製備根據申請專利範圍第1或2項之錠劑之方法,其 中先將法西克樂維耳與賦形劑製成顆粒,然後壓成錠。 本纸張AA制tBB家搞準〖CNS ) A4iUS· ( 21GX297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9600847.9A GB9600847D0 (en) | 1996-01-16 | 1996-01-16 | Pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
TW434016B true TW434016B (en) | 2001-05-16 |
Family
ID=10787105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW086100335A TW434016B (en) | 1996-01-16 | 1997-01-14 | Pharmaceutical tablet containing famciclovir and a process for its preparation |
Country Status (38)
Country | Link |
---|---|
US (1) | US6765007B1 (zh) |
EP (1) | EP0874632B1 (zh) |
JP (2) | JP4711360B2 (zh) |
KR (1) | KR100338829B1 (zh) |
CN (1) | CN1132582C (zh) |
AP (2) | AP747A (zh) |
AR (1) | AR005456A1 (zh) |
AT (1) | ATE220910T1 (zh) |
AU (1) | AU713090B2 (zh) |
BG (1) | BG63488B1 (zh) |
BR (1) | BR9706982A (zh) |
CY (1) | CY2390B1 (zh) |
CZ (1) | CZ287205B6 (zh) |
DE (1) | DE69714215T2 (zh) |
DK (1) | DK0874632T3 (zh) |
DZ (1) | DZ2159A1 (zh) |
EA (1) | EA001946B1 (zh) |
EG (1) | EG23684A (zh) |
ES (1) | ES2180922T3 (zh) |
GB (1) | GB9600847D0 (zh) |
HK (1) | HK1016473A1 (zh) |
HU (1) | HU225472B1 (zh) |
IL (1) | IL124913A0 (zh) |
MX (1) | MX9805713A (zh) |
MY (1) | MY127527A (zh) |
NO (1) | NO315689B1 (zh) |
NZ (1) | NZ326769A (zh) |
OA (1) | OA10812A (zh) |
PE (1) | PE35498A1 (zh) |
PL (1) | PL187291B1 (zh) |
PT (1) | PT874632E (zh) |
SK (1) | SK282132B6 (zh) |
TR (1) | TR199800954T2 (zh) |
TW (1) | TW434016B (zh) |
UA (1) | UA63897C2 (zh) |
UY (2) | UY24437A1 (zh) |
WO (1) | WO1997025990A1 (zh) |
ZA (1) | ZA97310B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
KR101710148B1 (ko) | 2009-06-26 | 2017-02-27 | 타리스 바이오메디컬 엘엘씨 | 이식가능한 약물전달 디바이스에 사용되기 위한 고체 약물 정제 |
JP2015063521A (ja) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | 高い薬物含有率を有する錠剤及びその製造方法 |
CN104434852B (zh) * | 2013-09-18 | 2018-11-20 | 北京韩美药品有限公司 | 泛昔洛韦直压片及其制备方法 |
CN112587491B (zh) * | 2021-01-03 | 2022-08-23 | 迪沙药业集团有限公司 | 一种泛昔洛韦片组合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3421800C1 (de) * | 1984-06-12 | 1986-04-17 | Maschinen und Werkzeugbau Michael Brümmer GmbH, 8804 Dinkelsbühl | Elastische Walze zum Behandeln einer thermoplastischen Folie |
DE3582399D1 (de) * | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
DE69207656T2 (de) * | 1991-01-30 | 1996-10-17 | Wellcome Found | Wasserlösliche tabletten |
EP0586523A4 (en) | 1991-05-15 | 1995-11-29 | Univ Yale | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
GB9303157D0 (en) * | 1993-02-17 | 1993-03-31 | Scotia Holdings Plc | Treatment of a group of related disorders |
IL111138A (en) | 1993-10-05 | 1997-04-15 | Smithkline Beecham Plc | Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia |
JP3702594B2 (ja) * | 1997-08-07 | 2005-10-05 | 株式会社明電舎 | パラメータ調節方法及び装置 |
-
1996
- 1996-01-16 GB GBGB9600847.9A patent/GB9600847D0/en active Pending
-
1997
- 1997-01-02 AP APAP/P/1997/000911A patent/AP747A/en active
- 1997-01-10 UY UY24437A patent/UY24437A1/es not_active IP Right Cessation
- 1997-01-13 EP EP97901539A patent/EP0874632B1/en not_active Expired - Lifetime
- 1997-01-13 HU HU9901021A patent/HU225472B1/hu unknown
- 1997-01-13 WO PCT/EP1997/000195 patent/WO1997025990A1/en active IP Right Grant
- 1997-01-13 DK DK97901539T patent/DK0874632T3/da active
- 1997-01-13 AU AU15418/97A patent/AU713090B2/en not_active Expired
- 1997-01-13 PT PT97901539T patent/PT874632E/pt unknown
- 1997-01-13 IL IL12491397A patent/IL124913A0/xx not_active IP Right Cessation
- 1997-01-13 AT AT97901539T patent/ATE220910T1/de active
- 1997-01-13 ES ES97901539T patent/ES2180922T3/es not_active Expired - Lifetime
- 1997-01-13 US US09/101,926 patent/US6765007B1/en not_active Expired - Lifetime
- 1997-01-13 CN CN97191703A patent/CN1132582C/zh not_active Expired - Lifetime
- 1997-01-13 CZ CZ19982254A patent/CZ287205B6/cs not_active IP Right Cessation
- 1997-01-13 EA EA199800573A patent/EA001946B1/ru not_active IP Right Cessation
- 1997-01-13 TR TR1998/00954T patent/TR199800954T2/xx unknown
- 1997-01-13 JP JP52569297A patent/JP4711360B2/ja not_active Expired - Lifetime
- 1997-01-13 NZ NZ326769A patent/NZ326769A/xx not_active IP Right Cessation
- 1997-01-13 UA UA98063199A patent/UA63897C2/uk unknown
- 1997-01-13 BR BR9706982A patent/BR9706982A/pt not_active IP Right Cessation
- 1997-01-13 AP APAP/P/1998/001298A patent/AP1114A/en active
- 1997-01-13 DE DE69714215T patent/DE69714215T2/de not_active Expired - Lifetime
- 1997-01-13 SK SK956-98A patent/SK282132B6/sk not_active IP Right Cessation
- 1997-01-13 PL PL97327922A patent/PL187291B1/pl unknown
- 1997-01-13 KR KR1019980705371A patent/KR100338829B1/ko not_active IP Right Cessation
- 1997-01-14 AR ARP970100130A patent/AR005456A1/es active IP Right Grant
- 1997-01-14 TW TW086100335A patent/TW434016B/zh not_active IP Right Cessation
- 1997-01-14 EG EG4697A patent/EG23684A/xx active
- 1997-01-15 DZ DZ970004A patent/DZ2159A1/fr active
- 1997-01-15 MY MYPI97000137A patent/MY127527A/en unknown
- 1997-01-15 ZA ZA9700310A patent/ZA97310B/xx unknown
- 1997-01-15 PE PE1997000022A patent/PE35498A1/es not_active IP Right Cessation
- 1997-05-16 UY UY24556A patent/UY24556A1/es not_active IP Right Cessation
-
1998
- 1998-07-15 MX MX9805713A patent/MX9805713A/es unknown
- 1998-07-15 BG BG102638A patent/BG63488B1/bg unknown
- 1998-07-15 NO NO19983259A patent/NO315689B1/no not_active IP Right Cessation
- 1998-07-16 OA OA9800116A patent/OA10812A/en unknown
-
1999
- 1999-04-08 HK HK99101423A patent/HK1016473A1/xx not_active IP Right Cessation
-
2003
- 2003-11-28 CY CY0300085A patent/CY2390B1/xx unknown
-
2008
- 2008-11-19 JP JP2008295818A patent/JP2009091362A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3773920A (en) | Sustained release medicinal composition | |
TW436294B (en) | Stable pharmaceutical composition for treating hyperlipemia and atherosclerosis | |
TW492878B (en) | Tablet composition | |
TW493984B (en) | Pharmaceutical composition comprising ibuprofen and codeine and preparation thereof | |
EP2005945B1 (en) | Oseltamivir phosphate granule and preparation method thereof | |
SA517390473B1 (ar) | أشكال جرعة صلبة من بالبوسيكليب | |
KR100384264B1 (ko) | 습식과립화에의한 투여단위의제조방법 | |
JPS611613A (ja) | 溶解度の低い薬物の経口用薬剤組成物 | |
JPS63301820A (ja) | 製薬学的錠剤、製薬学的顆粒及びそれらの製法 | |
JPH10512564A (ja) | コロイド状二酸化ケイ素を含むバラシクロビール錠剤 | |
JP3718341B2 (ja) | 低置換度ヒドロキシプロピルセルロースとその製造方法 | |
TW508242B (en) | Pharmaceutical composition comprising paracetamol | |
JP2017105815A (ja) | 安定な医薬組成物 | |
JPH10501537A (ja) | (s)−2−(4−イソブチルフェニル)プロピオン酸を活性成分とし、微結晶セルロースおよびコロイダルシリカを賦形剤とする固形医薬組成物 | |
TW434016B (en) | Pharmaceutical tablet containing famciclovir and a process for its preparation | |
KR0177493B1 (ko) | 단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법 | |
TW528605B (en) | Anion exchange resin-containing tablets | |
JP2009091362A6 (ja) | 高含量ファムシクロビル錠剤 | |
US3019169A (en) | Salicylate dry shell coating of dry 4-aminoquinoline core, and dry-compressing tablet-making process | |
CN110960501B (zh) | 一种诺氟沙星胶囊及其制备方法 | |
JPS6346726B2 (zh) | ||
JPS59210022A (ja) | テオフイリン徐放性製剤 | |
JP4591726B2 (ja) | メキタジン含有内服固形製剤 | |
CN100435797C (zh) | 茚地那韦口服速释制剂及制备方法 | |
CN103768029B (zh) | 一种高稳定性的拉呋替丁片及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |